Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/27697287/ below:

The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies

Affiliations

• ¹ Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
• ² Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
• ³ Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
• ⁴ Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Electronic address: temkinsm@mail.nih.gov.

• PMID: 27697287
• DOI: 10.1016/j.ygyno.2016.09.026

Item in Clipboard

Grace Mishkin et al. Gynecol Oncol. 2016 Dec.

• ¹ Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
• ² Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
• ³ Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
• ⁴ Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Electronic address: temkinsm@mail.nih.gov.

• PMID: 27697287
• DOI: 10.1016/j.ygyno.2016.09.026

Item in Clipboard

Objectives: Enrollment of a representative population to cancer clinical trials ensures scientific reliability and generalizability of results. This study evaluated the similarity of patients enrolled in NCI-supported group gynecologic cancer trials to the incident US population.

Methods: Accrual to NCI-sponsored ovarian, uterine, and cervical cancer treatment trials between 2003 and 2012 were examined. Race, ethnicity, age, and insurance status were compared to the analogous US patient population estimated using adjusted SEER incidence data.

Results: There were 18,913 accruals to 156 NCI-sponsored gynecologic cancer treatment trials, ovarian (56%), uterine (32%), and cervical cancers (12%). Ovarian cancer trials included the least racial, ethnic and age diversity. Black women were notably underrepresented in ovarian trials (4% versus 11%). Hispanic patients were underrepresented in ovarian and uterine trials (4% and 5% versus 18% and 19%, respectively), but not in cervical cancer trials (14 versus 11%). Elderly patients were underrepresented in each disease area, with the greatest underrepresentation seen in ovarian cancer patients over the age of 75 (7% versus 29%). Privately insured women were overrepresented among accrued ovarian cancer patients (87% versus 76%), and the uninsured were overrepresented among women with uterine or cervical cancers. These patterns did not change over time.

Conclusions: Several notable differences were observed between the patients accrued to NCI funded trials and the incident population. Improving representation of racial and ethnic minorities and elderly patients on cancer clinical trials continues to be a challenge and priority.

Keywords: Clinical trials; Disparities; SEER.

Copyright © 2016 Elsevier Inc. All rights reserved.

PubMed Disclaimer

• Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials.

  Mattei LH, Robb L, Banning K, Polan RM, Cote ML. Mattei LH, et al. Obstet Gynecol. 2022 Oct 1;140(4):654-661. doi: 10.1097/AOG.0000000000004917. Epub 2022 Sep 7. Obstet Gynecol. 2022. PMID: 36075065

• Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis.

  Albright BB, Nasioudis D, Craig S, Moss HA, Latif NA, Ko EM, Haggerty AF. Albright BB, et al. Am J Obstet Gynecol. 2021 Feb;224(2):195.e1-195.e17. doi: 10.1016/j.ajog.2020.08.007. Epub 2020 Aug 7. Am J Obstet Gynecol. 2021. PMID: 32777264 Free PMC article.

• Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer.

  Khadraoui W, Meade CE, Backes FJ, Felix AS. Khadraoui W, et al. JAMA Netw Open. 2023 Dec 1;6(12):e2346494. doi: 10.1001/jamanetworkopen.2023.46494. JAMA Netw Open. 2023. PMID: 38060227 Free PMC article.

• Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes.

  Tammemagi CM. Tammemagi CM. Curr Opin Obstet Gynecol. 2007 Feb;19(1):31-6. doi: 10.1097/GCO.0b013e3280117cf8. Curr Opin Obstet Gynecol. 2007. PMID: 17218849 Review.

• Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

  Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Collins Y, et al. Gynecol Oncol. 2014 May;133(2):353-61. doi: 10.1016/j.ygyno.2013.12.039. Epub 2014 Jan 7. Gynecol Oncol. 2014. PMID: 24406291 Free PMC article. Review.

• "Ultimately, mom has the call": Viewing clinical trial decision making among patients with ovarian cancer through the lens of relational autonomy.

  Asiedu GB, Ridgeway JL, Carroll K, Jatoi A, Radecki Breitkopf C. Asiedu GB, et al. Health Expect. 2018 Dec;21(6):981-989. doi: 10.1111/hex.12691. Epub 2018 Apr 14. Health Expect. 2018. PMID: 29655265 Free PMC article.

• New strategies in ovarian cancer treatment.

  Lee JM, Minasian L, Kohn EC. Lee JM, et al. Cancer. 2019 Dec 15;125 Suppl 24(Suppl 24):4623-4629. doi: 10.1002/cncr.32544. Cancer. 2019. PMID: 31967682 Free PMC article. Review.

• Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum.

  McAlarnen LA, Tsaih SW, Aliani R, Simske NM, Hopp EE. McAlarnen LA, et al. Gynecol Oncol. 2021 Jul;162(1):4-11. doi: 10.1016/j.ygyno.2021.04.037. Epub 2021 May 11. Gynecol Oncol. 2021. PMID: 33994014 Free PMC article.

• Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion.

  Cushman TR, Haque W, Menon H, Rusthoven CG, Butler EB, Teh BS, Verma V. Cushman TR, et al. J Gynecol Oncol. 2018 Nov;29(6):e97. doi: 10.3802/jgo.2018.29.e97. J Gynecol Oncol. 2018. PMID: 30207105 Free PMC article.

• Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico.

  Kunos CA, Massett HA, Galassi A, Walker JL, Good MJ, Díaz LB, McCaskill-Stevens W. Kunos CA, et al. Front Oncol. 2018 Apr 10;8:102. doi: 10.3389/fonc.2018.00102. eCollection 2018. Front Oncol. 2018. PMID: 29692980 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3